Bridge BioResearch

We are a drug development company with the sole corporate focus on obesity and metabolic disorders

Incidence and prevalence of diabetes mellitus are increasing worldwide, in line with lifestyle changes and population aging. In particular, the rising prevalence of diabetes is closely linked with that of obesity, creating significant market opportunities. The World Health Organization estimates the number of diabetics to exceed 350 million by 2030. Governments and other healthcare providers around the world are investing in health education, diagnosis and treatments for this chronic, debilitating - but controllable - disorder.

(World Diabetes Market Analysis, 2009-2023,
Pharmaceutical Report from Visiongain UK, 2009)

• Blockbuster potential in the acquired patents and patent applications, which could lead to a drug to cure metabolic disorders.

• Rapid advancements reducing time to market and accelerating milkestone payments and royalty streams

- One diabetes target for which patient recruitment for phase 2a has commenced
- One obesity in preclinical trials

• A world-class management team of experts with more than a century of combined experience in obesity and metabolic disorder research, complemented by an advisory board with recognized as outstanding international scientists.

• Access to international high quality cost-efficient research engines, benefiting from the excess capacity in the sector. Research cooperation agreements with leading R&D Service Providers, research institutions and universities in the US, Canada, India and Europe (UK, France,Denmark).

• Unique cost-efficient technology and patent acquisition strategy for proprietary intellectual property (IP) from identified companies, government institutions and universities, paid via milestone-dependent research collaboration and grants.

• IP acquisitions pending with leading universities and institutions in Europe, China and India, including two already identified cost-efficient technology targets. Flexible execution strategy as technology can be on "loan" to Bridge BioResearch for evaluation before substantial investment is committed.